Entera Bio (FRA:5DT) Long-Term Debt : €0.00 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Entera Bio Long-Term Debt?

Entera Bio's Long-Term Debt for the quarter that ended in Mar. 2024 was €0.00 Mil.

Entera Bio Long-Term Debt Historical Data

The historical data trend for Entera Bio's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entera Bio Long-Term Debt Chart

Entera Bio Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

Entera Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Entera Bio (FRA:5DT) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Entera Bio Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Entera Bio's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Entera Bio (FRA:5DT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entera Bio Ltd (FRA:5DT) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

ENTX:USA

Address

Minrav Building - Fifth Floor, Kiryat Hadassah, Jerusalem, ISR, 9112002

Website

https://www.enterabio.com

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Entera Bio (FRA:5DT) Headlines

No Headlines